Testosterone optimization in men

The premise

Testosterone replacement therapy is the cleanest "optimization" intervention in the Nimbus catalogue — and the easiest to get wrong by reflex. The pre-2024 era was dominated by fear of cardiovascular and prostate-cancer harm. TRAVERSE 2023^{[TRAVERSE-2023]} randomized 5,204 men with hypogonadism and preexisting or high CV risk to transdermal testosterone vs. placebo and found no increase in major adverse cardiovascular events. The FDA removed the MACE black-box warning in February 2025 (with a new caution that some oral testosterone products may raise blood pressure).

What's left is a gating problem. The Nimbus protocol gets the gating right by anchoring on three ideas that mainstream urology often does not foreground:

1. The saturation model — prostate androgen receptors saturate at roughly 250 ng/dL total testosterone. Therapeutic TRT above that does not proportionally increase prostate-cancer risk, so "his testosterone is high" is not by itself a reason to hold.
2. Free T over Total T — total T is bound to SHBG and albumin and does not always correlate with symptoms. Free T does. A 48-year-old with Total T 926 ng/dL and low libido can still be hypogonadal at the free-T level.
3. Fertility first under 40 — men under 40 with hypogonadism get a clomiphene or hCG trial before exogenous T, plus a prolactin to rule out pituitary adenoma.

Pre-test — anchor the saturation model

TRT physiology — the saturation model, total vs. free, why E2 still matters

Testosterone circulates ~98% bound (SHBG, albumin) and ~2% free. The free fraction is what drives androgen-receptor signaling and symptom resolution. Total T is misleading when SHBG is high (aging, hyperthyroidism, oral E2) or low (insulin resistance, obesity). The Nimbus protocol gates on Free T, not Total T.

Inside the prostate, the androgen receptor saturates at approximately 250 ng/dL total testosterone. Past that point additional T does not further accelerate prostate growth — which is the rational basis for not reflexively holding TRT on the strength of a high T level alone.

A second physiologic anchor: testosterone aromatizes to estradiol. In men, E2 is the dominant regulator of bone health — androgen-deprivation states show bone, brain, and CV consequences that track E2 suppression more than T suppression^{[Falahati-Nini-2000]}. That is why routine aromatase inhibition is not a Nimbus default (see the AI section below).

Initiation — subcutaneous is the default

Subcutaneous testosterone is the Nimbus first-line. Patients self-administer in the abdomen or thigh with an insulin-style syringe. Compared to intramuscular: smaller needle, less peak-trough swing, easier home use, better adherence. The FDA label for testosterone cypionate / enanthate is IM — subcutaneous use is off-label, with the rationale and counseling documented per Nimbus policy.

Reassess at 8–12 weeks with symptoms, Free T, Hct, and PSA (if ≥40). Symptom resolution within the optimal Free T range is the endpoint — do not chase a single lab number.

Alternate routes

Free T target — Quest vs. LabCorp

The single most common mistake in TRT interpretation is reading a Free T value without asking which vendor produced it. Quest and LabCorp use different free-T assay methodologies and report different "normal" ranges. The Nimbus optimal targets are vendor-aware: roughly 170–210 pg/mL on Quest, 30–40 pg/mL on LabCorp. Use the converter below as a quick check before dose adjustments.

PSA gating — percent-free PSA and the prostatitis pathway

Pre-TRT baseline PSA + digital rectal exam (DRE) in men ≥40 with risk factors or ≥55 generally. Annual PSA on TRT at minimum. 3-day pre-draw prep: no vigorous exercise, no cycling, no sexual activity, no DRE — all of which transiently raise PSA.

If PSA exceeds 2.5 ng/mL on TRT, recheck and order percent-free PSA. The decision tree below mirrors the Nimbus protocol:

Suspected prostatitis as the cause of a PSA bump gets an empiric course of TMP-SMX 800/160 mg PO q12h × 14 days (extend to 21–30 days if persistent); alt cephalexin 500 mg PO q12h × 14 days. Retest PSA 3–4 months after completion. Caveats on PSA interpretation:

• 5α-reductase inhibitors (finasteride / dutasteride) lower PSA roughly 50% with no effect on percent-free.
• Statins, NSAIDs, acetaminophen, and thiazides also pull PSA down.
• Recent sex, exercise, cycling, DRE, instrumentation, or a hard bowel movement transiently push PSA up.

Urology referral triggers: PSA rise >1.4 ng/mL above baseline within 12 months; PSA >4.0 ng/mL; abnormal DRE; percent-free PSA <10%.

Hct gating — and the OSA workup hidden inside it

The most common dose-limiting side effect of TRT is hematocrit rise. The Nimbus protocol:

• Hct ≥52% — reduce dose or extend interval; consider blood donation.
• Hct ≥54% — HOLD therapy; phlebotomy if symptomatic; workup OSA (STOP-Bang).
• Untreated severe OSA is the most common reversible cause; high-altitude residence (>~3,000 m / 10,000 ft) is a benign physiologic adaptation and may not require intervention.

Frame this for the patient as a workup gate, not a punishment — the secondary erythrocytosis is usually telling you something about sleep-disordered breathing.

Under-40 men — fertility first, prolactin to rule out adenoma

Mainstream practice often treats hypogonadism the same way regardless of age. Nimbus diverges: men under 40 with confirmed symptomatic hypogonadism get a clomiphene or hCG trial before exogenous testosterone. Reasoning:

• Exogenous T suppresses GnRH → LH/FSH → spermatogenesis; testicular atrophy and infertility follow.
• Clomiphene 25–50 mg QOD (off-label) is a SERM that increases endogenous LH/FSH and preserves spermatogenesis.
• hCG 500–1,500 IU SC 2–3×/week (off-label) directly stimulates Leydig cells.
• Both are reversible. Exogenous T's fertility effects are not always reversible.

Concurrent with the fertility decision, check prolactin. Prolactin >40 ng/mL in a young hypogonadal man is a red flag for pituitary adenoma — work that up before any androgen therapy.

AI in men — why routine use is wrong

Routine aromatase inhibitor co-prescription with TRT is one of the most common "optimization" errors. Estradiol in men is not a side effect to be suppressed — it is the dominant regulator of bone, is required for libido / cognition / joint comfort, and its suppression in androgen-deprivation patients drives the worst quality-of-life sequelae^{[Finkelstein-2013]}.

The Nimbus approach when E2 is symptomatic:

1. Reduce dose — many "high E2" symptoms resolve at a lower T dose.
2. Increase frequency — splitting weekly into 2× weekly (or going daily SC) flattens the E2 peak.
3. Reserve low-dose AI (e.g., anastrozole) only for symptomatic estrogen excess refractory to (1) and (2), and time-limit it (1–2 months, then reassess).

Counsel patients about the costs of routine AI: low libido, ED, mood lability, visceral fat gain, bone loss, joint pain, increased CAD/CVA/mortality signals when used routinely in men.

5α-RI in men — finasteride / dutasteride are not first-line on TRT

Routine co-prescription of finasteride or dutasteride with TRT to prevent hair loss is not a Nimbus default. Two reasons:

• DHT is required for orgasm and sexual function. Blunting it can erase a meaningful fraction of the TRT benefit.
• Post-finasteride syndrome (PFS) — persistent sexual, neurological, and physical adverse effects after discontinuation, potentially irreversible. Counseling about PFS is required before any 5α-RI Rx.

If a patient explicitly wants a 5α-RI for hair loss after counseling and optimization of ferritin (>80) and thyroid: finasteride 1 mg/day (lowers PSA ~50% with no effect on percent-free) or dutasteride 0.5 mg twice weekly. Topical minoxidil 5% (or oral minoxidil 1.25 mg/day) is the first-line hair-loss option.

TRAVERSE — what the cardiovascular safety data actually showed

TRAVERSE 2023^{[TRAVERSE-2023]} randomized 5,204 hypogonadal men aged 45–80 with preexisting or high CV risk to 1.62% transdermal testosterone vs. placebo, mean follow-up 21.7 months. The primary endpoint (composite of CV death, non-fatal MI, non-fatal stroke) was non-inferior in the T arm. There was a small numeric increase in atrial fibrillation, acute kidney injury, and pulmonary embolism — flagged in labeling but not enough to support the pre-2025 MACE black-box.

The clinical implication is conservative but real: in symptomatic hypogonadal men with or without CV risk, TRT does not measurably worsen MACE within roughly 2 years of treatment. The FDA removed the MACE black-box in February 2025 and added a BP-caution, particularly for newer oral testosterone products.

TODO(citation): AUA TRT guideline (Mulhall et al. 2018, updated) for the mainstream comparator framing of Total T as primary gating diagnostic. Search PubMed when finalizing.

TODO(citation): Tomic et al. for clomiphene in male hypogonadism — confirm PMID before publication.

TODO(citation): Yassin et al. 2023 long-term TTh in hypogonadal men (LUTS endpoint) — confirm PMID.

TODO(citation): McHenry et al. 2014 review on testosterone, mood, and depression — confirm PMID.

TODO(citation): Jung 2016 prospective placebo-controlled trial of TRT for cognition in hypogonadal men — confirm PMID.

TODO(citation): Okada 2016 IM testosterone enanthate / LUTS — confirm PMID.

Transference — the household-contact counseling

Topical testosterone transfers to partners, children, and pets via skin contact and contaminated fabrics. Transference is teratogenic to a fetus. Counsel every topical patient:

• Apply ~4 hours before bedtime (the Nimbus default for scrotal cream).
• Wash hands thoroughly with soap after application.
• Use separate towels and washcloths from children and pregnant / nursing partners.
• Wash clothes and bedsheets separately.
• Not an issue with injectables, orals, or pellets — only topicals.

If a household partner is pregnant or nursing, switch route (SC injection is the simplest swap) or apply with the strictest transference protocol.

Track branches

Post-test — synthesis

Module evaluation